Arthritis Patents (Class 514/825)
  • Patent number: 10077320
    Abstract: Efficient cross-linking of hyaluronic acid (HA) is provided by a manufacturing process. In the process, HA is activated by an initial cross-linking in an aqueous solution. Unreacted cross-linking agent is removed from the activated HA. Cross-linking of the activated HA is finalized, without addition of any additional cross-linking agent, in a suspension of a liquid precipitating medium and the activated HA in precipitated form. The resulting cross-linked HA products exhibit high effective cross-linker ratio and other favorable properties, making the products useful as implants and in medical and cosmetic surgery.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: September 18, 2018
    Assignee: GALDERMA S.A.
    Inventors: Morgan Karlsson, Katarina Edsman
  • Patent number: 9623157
    Abstract: This invention relates to hydrophilic polymer compositions and a preferred application therefore, viz., hydrophilic medical device coatings. The hyaluronic acid hyaluronon by itself or modified as described herein advantageously reacts with compositions disclosed in U.S. Pat. No. 7,776,956 to produce hydrophilic compositions and coatings particularly useable with medical devices.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 18, 2017
    Assignee: Lake Region Manufacturing, Inc.
    Inventor: Peter Anthony Edwards
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 9023831
    Abstract: A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 5, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 8986735
    Abstract: A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer and a taste masked ketoprofen active. Also provided are methods for preparing the solid dosage form and for using the solid dosage to administer an effective dosage of an active agent, such as ketoprofen, into the oral cavity for absorption.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Alexander M Schobel, Shyam S Vangala
  • Patent number: 8906966
    Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 9, 2014
    Inventors: Paul Sherwood, David Keith Davies
  • Patent number: 8809358
    Abstract: The present invention relates to the use of I?B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: August 19, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Martin Michaelis, Olaf Ritzeler, Gerhard Jaehne, Karl Rudolphi, Gerd Geisslinger, Hans-Georg Schaible
  • Patent number: 8691842
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: April 8, 2014
    Assignees: Catholic University Industry Academic Cooperation Foundation, Hanlim Pharmaceutical Co., Ltd.
    Inventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Joo-Yeon Jhun, Geun-Hyeog Lee, Se-Wan Park, Jin-Ha Park, Eun-Young Kwak
  • Patent number: 8691796
    Abstract: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: April 8, 2014
    Assignee: China Medical University
    Inventors: Feng-Huei Lin, Teng-Le Huang, Horng-Chaung Hsu
  • Patent number: 8623408
    Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral and buccal administration of cladribine.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: January 7, 2014
    Assignee: Ares Trading S.A.
    Inventor: Nicholas S Bodor
  • Patent number: 8617536
    Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: December 31, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
  • Patent number: 8609730
    Abstract: This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: December 17, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Youhai H. Chen, Ramachandran Murali, Jing Sun
  • Patent number: 8557865
    Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: October 15, 2013
    Assignee: Calosyn Pharma, Inc.
    Inventor: David D. Waddell
  • Patent number: 8440893
    Abstract: When C60 was added to synovial fibroblasts, infiltrating lymphocytes, and macrophages, and the inflammatory cytokine production level was measured, the inflammatory cytokine production level was significantly suppressed in all cells. Furthermore, when C60 was added to osteoclast precursor cells and cultured in the presence of osteoclast differentiation-inducing factors, a certain concentration or more of C60 suppressed their differentiation into osteoclasts. Observation of the effect of C60 addition on bone resorption showed that C60 suppressed bone resorption by osteoclasts. In addition, the use of arthritis model animals confirmed in vivo that C60 suppressed inflammatory symptoms, as well as bone resorption and bone destruction by osteoclasts. C60 is effective for treating arthritic diseases such as rheumatoid arthritis through its effects of suppressing osteoclast differentiation, bone resorption, and inflammatory cytokines.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: May 14, 2013
    Assignees: St. Marianna University School of Medicine, Mitsubishi Corporaion
    Inventor: Kazuo Yudoh
  • Patent number: 8420135
    Abstract: A method for treating immunological diseases and/or disorders associated with tumor necrosis factor-alpha (TNF-?) in a subject in need thereof is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of the coconut (Cocos nucifera Linn.) water extract or coconut (Cocos nucifera Linn.) shell extract through induction of transforming growth factor beta (TGF-?) or interleukin-10 (IL-10) as endogenous immunosuppressive factors.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 16, 2013
    Inventor: Rong-Tsun Wu
  • Patent number: 8395037
    Abstract: Fullerene inhibited the decrease in cell proliferation ability of chondrocytes which is observed when cultured chondrocytes are treated with a cartilage degenerating factor (IL-1? or H2O2). Fullerene inhibited production of cartilage matrix-degrading enzymes (matrix metalloprotease (MMP)-1, 3 and 13) which is induced in cultured chondrocytes by cartilage degenerating factors. Fullerene restored the decrease in cartilage matrix (proteoglycan) synthesizing ability which is observed in treating cultured chondrocytes with cartilage degenerating factors. In an analysis using an osteoarthritis rabbit model, the progress of cartilage degeneration was reduced by administering fullerene. Moreover, the dynamic friction coefficient was decreased by adding fullerene to synovial fluid.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: March 12, 2013
    Assignees: Mitsubishi Corporation, St. Marianna University School of Medicine
    Inventor: Kazuo Yudoh
  • Patent number: 8357515
    Abstract: The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: January 22, 2013
    Assignee: Queen Mary & Westfield College
    Inventors: Yuti Chernajovsky, Gillian Adams
  • Patent number: 8329637
    Abstract: The invention discloses a combined preparation containing IL-10 and rapamycin, able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune responses mediated by T cells.
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: December 11, 2012
    Inventors: Maria Grazia Roncarolo, Manuela Battaglia
  • Patent number: 8329746
    Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: December 11, 2012
    Assignee: CaloSyn Pharma, Inc.
    Inventor: David D. Waddell
  • Patent number: 8324165
    Abstract: The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: December 4, 2012
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Kalyani Penta, Srinivas Kothakota, Lewis T. Williams, Kevin Hestir, Shannon Marshall, Jeffrey Finer, Yan Wang
  • Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 8231874
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: July 31, 2012
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: 8221748
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 17, 2012
    Assignee: Baylor Research Institute
    Inventors: Jacques Banchereau, Virginia Pascual
  • Patent number: 8211947
    Abstract: The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: July 3, 2012
    Inventor: Guillermo Selman-Housein Sosa
  • Patent number: 8207151
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: June 26, 2012
    Assignee: Validus Biopharma Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Patent number: 8198401
    Abstract: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid Arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of Rheumatoid Arthritis.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: June 12, 2012
    Assignee: London Health Sciences Centre Research Inc.
    Inventors: Jonathan Hill, Ewa Cairns, David Bell
  • Patent number: 8129383
    Abstract: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 6, 2012
    Assignee: Aminopterin LLC
    Inventors: John Zebala, Barton A. Kamen
  • Patent number: 8080540
    Abstract: Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17?-hydroxysteroid dehydrogenase (17?-HSD) such as 17?-HSD type 1, type 2 or type 3 enzyme.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: December 20, 2011
    Assignee: Abbott Products GmbH
    Inventors: Josef Messinger, Uwe Schoen, Heinrich-Hubert Thole, Bettina Husen, Pasi Koskimies, Lila Kallio nee Pirkkala
  • Patent number: 8012475
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: 7999010
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: August 16, 2011
    Assignee: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7955598
    Abstract: A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: June 7, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazuyuki Yoshizaki, Norihiro Nishimoto, Masahiro Iwamoto, Seiji Minota, Shumpei Yokota, Takako Miyamae
  • Patent number: 7931901
    Abstract: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: April 26, 2011
    Assignees: The Brigham and Women's Hospital, Inc.
    Inventors: Nalan Utku, Steven R. Gullans, Edgar L. Milford
  • Patent number: 7883703
    Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: February 8, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard L. Weiner, Mohamed H. Sayegh
  • Patent number: 7851458
    Abstract: A food supplement, either in the form of a snack bar or a beverage, which contains one or more cartilage enhancing supplements is provided. The cartilage supplements include chondroitin, glucosamine, and hyaluronic acid. The food supplement may additionally be fortified with cetyl myristoleate. The beverage is a mixture of a juice drink base which may include a water-based fruit flavored juice prepared using a pasteurization process at a relatively high temperature and a cartilage supplement solution which includes a cartilage supplement prepared at a relatively low temperature. The beverage may be carbonated, non-carbonated or concentrated. The preferred cartilage supplement is glucosamine, preferably associated with a counter ion, more preferably as glucosamine HCl. The supplement also contains vitamin C (ascorbic acid) and calcium hydroxide powder.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 14, 2010
    Assignee: Joint Juice, Inc.
    Inventor: Kevin R. Stone
  • Patent number: 7820169
    Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: October 26, 2010
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 7812029
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: October 12, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • Patent number: 7776914
    Abstract: The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: August 17, 2010
    Assignee: Imagenetix, Inc.
    Inventors: William P. Spencer, Patrick S. Millsap
  • Patent number: 7767710
    Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: August 3, 2010
    Assignee: Calosyn Pharma, Inc.
    Inventor: David D. Waddell
  • Patent number: 7741292
    Abstract: A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further activation.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: June 22, 2010
    Assignee: IPF Pharmaceuticals GmbH
    Inventors: Ulf Forssmann, Jörn Elsner, Sylvia Escher, Nikolaj Spodsberg
  • Patent number: 7713951
    Abstract: 2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: May 11, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Rafal Barycki, Pawel K. Grzywacz, Lori A. Plum, Rafal R. Sicinski
  • Patent number: 7671028
    Abstract: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: March 2, 2010
    Assignees: POSTECH Foundation, POSCO, POSTECH Academy-Industry Foundation
    Inventors: Pann-Ghill Suh, Yoe-Sik Bae, Sung Ho Ryu, Tae Hoon Lee, Ha Young Lee, Eun Jin Jo, Jung-Im Kim, Hyun-Kyu Kang, Richard D. Ye, Jong-Young Kwak
  • Patent number: 7671020
    Abstract: The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 2, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin
  • Patent number: 7652143
    Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: January 26, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Andreas Lindenschmidt, Holger Wagner, Jochen Beninga, Sven Grueneberg, Klaus-ulrich Weithmann
  • Patent number: 7622110
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: November 24, 2009
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Patent number: 7615212
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: November 10, 2009
    Assignee: Baylor Research Institute
    Inventors: Jacques Banchereau, Virginia Pascual
  • Patent number: 7612111
    Abstract: The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: November 3, 2009
    Assignee: Imagenetix, Inc.
    Inventors: William P. Spencer, Patrick S. Millsap
  • Patent number: 7612110
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: November 3, 2009
    Assignee: Biogen Idec International AG
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Patent number: 7534430
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: May 19, 2009
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Patent number: RE42645
    Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 23, 2011
    Inventor: Albert Crum